Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros

Base de datos
Tópicos
Tipo del documento
Intervalo de año
1.
Sci Rep ; 12(1): 9641, 2022 06 10.
Artículo en Inglés | MEDLINE | ID: covidwho-1984413

RESUMEN

After more than 6 million deaths worldwide, the ongoing vaccination to conquer the COVID-19 disease is now competing with the emergence of increasingly contagious mutations, repeatedly supplanting earlier strains. Following the near-absence of historical examples of the long-time evolution of infectious diseases under similar circumstances, models are crucial to exemplify possible scenarios. Accordingly, in the present work we systematically generalize the popular susceptible-infected-recovered model to account for mutations leading to repeatedly occurring new strains, which we coarse grain based on tools from statistical mechanics to derive a model predicting the most likely outcomes. The model predicts that mutations can induce a super-exponential growth of infection numbers at early times, which self-amplify to giant infection waves which are caused by a positive feedback loop between infection numbers and mutations and lead to a simultaneous infection of the majority of the population. At later stages-if vaccination progresses too slowly-mutations can interrupt an ongoing decrease of infection numbers and can cause infection revivals which occur as single waves or even as whole wave trains featuring alternative periods of decreasing and increasing infection numbers. This panorama of possible mutation-induced scenarios should be tested in more detailed models to explore their concrete significance for specific infectious diseases. Further, our results might be useful for discussions regarding the importance of a release of vaccine-patents to reduce the risk of mutation-induced infection revivals but also to coordinate the release of measures following a downwards trend of infection numbers.


Asunto(s)
COVID-19 , Enfermedades Transmisibles , Susceptibilidad a Enfermedades , Humanos , Mutación , Vacunación
2.
Sci Rep ; 10(1): 21594, 2020 12 09.
Artículo en Inglés | MEDLINE | ID: covidwho-966852

RESUMEN

Present hopes to conquer the Covid-19 epidemic are largely based on the expectation of a rapid availability of vaccines. However, once vaccine production starts, it will probably take time before there is enough vaccine for everyone, evoking the question how to distribute it best. While present vaccination guidelines largely focus on individual-based factors, i.e. on the question to whom vaccines should be provided first, e.g. to risk groups or to individuals with a strong social-mixing tendency, here we ask if a strategic spatiotemporal distribution of vaccines, e.g. to prioritize certain cities, can help to increase the overall survival rate of a population subject to an epidemic disease. To this end, we propose a strategy for the distribution of vaccines in time and space, which sequentially prioritizes regions with the most new cases of infection during a certain time frame and compare it with the standard practice of distributing vaccines demographically. Using a simple statistical model we find that, for a locally well-mixed population, the proposed strategy strongly reduces the number of deaths (by about a factor of two for basic reproduction numbers of [Formula: see text] and by about 35% for [Formula: see text]). The proposed vaccine distribution strategy establishes the idea that prioritizing individuals not only regarding individual factors, such as their risk of spreading the disease, but also according to the region in which they live can help saving lives. The suggested vaccine distribution strategy can be tested in more detailed models in the future and might inspire discussions regarding the importance of spatiotemporal distribution rules for vaccination guidelines.


Asunto(s)
COVID-19 , Modelos Biológicos , Pandemias , SARS-CoV-2 , Vacunación , Vacunas Virales , COVID-19/mortalidad , COVID-19/prevención & control , Humanos , Vacunas Virales/provisión & distribución , Vacunas Virales/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA